Literature DB >> 21552233

Overhauling the reimbursement system for molecular diagnostics.

Nafees N Malik.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21552233     DOI: 10.1038/nbt.1869

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  A policy approach to the development of molecular diagnostic tests.

Authors:  Kevin A Schulman; Sean R Tunis
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

2.  Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay.

Authors:  Julia R Trosman; Stephanie L Van Bebber; Kathryn A Phillips
Journal:  J Oncol Pract       Date:  2010-09       Impact factor: 3.840

3.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

4.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Is personalized medicine finally arriving?

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2008-05       Impact factor: 54.908

6.  The Impact of CED On Private Payers.

Authors:  William Atkinson
Journal:  Biotechnol Healthc       Date:  2007-04

7.  Personalized medicine: factors influencing reimbursement.

Authors:  Lisa M Meckley; Peter J Neumann
Journal:  Health Policy       Date:  2009-10-07       Impact factor: 2.980

  7 in total
  1 in total

1.  Biomarker patents for diagnostics: problem or solution?

Authors:  Michael M Hopkins; Stuart Hogarth
Journal:  Nat Biotechnol       Date:  2012-06-07       Impact factor: 54.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.